Immunic (NASDAQ:IMUX) Raised to Strong-Buy at LADENBURG THALM/SH SH

Immunic (NASDAQ:IMUX) was upgraded by equities researchers at LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

IMUX has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a research note on Thursday, April 30th. Wolfe Research assumed coverage on Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. B. Riley Financial lowered their target price on Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Finally, D. Boral Capital downgraded Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Immunic has a consensus rating of “Buy” and a consensus price target of $47.57.

Immunic Price Performance

IMUX stock opened at $13.05 on Wednesday. The firm has a market cap of $177.74 million, a price-to-earnings ratio of -2.34 and a beta of 1.37. Immunic has a 1-year low of $5.06 and a 1-year high of $15.84. The firm has a fifty day moving average price of $14.24 and a two-hundred day moving average price of $11.41.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). As a group, analysts expect that Immunic will post -4.57 EPS for the current fiscal year.

Institutional Trading of Immunic

Hedge funds have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in Immunic during the 1st quarter valued at about $27,000. ADAR1 Capital Management LLC acquired a new stake in shares of Immunic in the first quarter valued at approximately $33,000. Qube Research & Technologies Ltd bought a new stake in shares of Immunic during the third quarter valued at approximately $29,000. Focus Partners Wealth raised its holdings in shares of Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Immunic during the third quarter worth approximately $52,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.